Cargando…
Adrenal gland inclusions in patients treated with aldosterone antagonists (Spironolactone/Eplerenone): incidence, morphology, and ultrastructural findings
ABSTRACT: BACKGROUND: Spironolactone is often used to treat hypertension caused by hyperaldosteronism, and as a result, can form concentrically laminated electron dense spironolactone body inclusions within the adrenal gland. Spironolactone bodies have not been investigated in a contemporary cohort...
Autores principales: | Patel, Kishan A, Calomeni, Edward P, Nadasdy, Tibor, Zynger, Debra L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261889/ https://www.ncbi.nlm.nih.gov/pubmed/25108298 http://dx.doi.org/10.1186/1746-1596-9-147 |
Ejemplares similares
-
Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
por: Pereira, Sofia S., et al.
Publicado: (2021) -
Eplerenone use in primary aldosteronism during pregnancy
por: Gunganah, Kirun, et al.
Publicado: (2015) -
Efficacy of mineralocorticoid receptor antagonism in the acute myocardial infarction phase: eplerenone versus spironolactone
por: Fraccarollo, Daniela, et al.
Publicado: (2015) -
The effect of eplerenone on the renin‐angiotensin‐aldosterone system of rats with thyroid dysfunction
por: Dizaye, Kawa, et al.
Publicado: (2019) -
Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy
por: Nakano, Yujiro, et al.
Publicado: (2018)